CTOs on the Move

Vera Therapeutics

www.veratx.com

 
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.veratx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.770.0077

Executives

Name Title Contact Details
Scott Rossi
Head of Cybersecurity Profile

Funding

Vera Therapeutics raised $80M on 01/19/2021

Similar Companies

BioFX Laboratories

BioFX Laboratories is a Owings Mills, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InforMed Direct

InforMed Direct is a Haddam, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AstraZeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.

Southeast Orthopedic Specialists

Our team of orthopedic surgeons and physical therapists serve Jacksonville, Orange Park and St. Augustine. We offer expert care for bones, muscles, and joints. Call (904) 634-0640 for an appointment!